These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 6424978)

  • 1. The effect of bromocriptine in the polycystic ovary syndrome.
    Spruce BA; Kendall-Taylor P; Dunlop W; Anderson AJ; Watson MJ; Cook DB; Gray C
    Clin Endocrinol (Oxf); 1984 Apr; 20(4):481-8. PubMed ID: 6424978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of bromocryptin in polycystic ovary syndrome].
    Fuhrer J; Cheviakoff S; Rubio V
    Rev Chil Obstet Ginecol; 1989; 54(6):364-9; discussion 369-70. PubMed ID: 2485372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of bromocriptine on LH pulsatility in the polycystic ovary syndrome.
    Chapman AJ; Wilson MD; Obhrai M; Sawers RS; Lynch SS; Royston JP; Clayton RN
    Clin Endocrinol (Oxf); 1987 Nov; 27(5):571-80. PubMed ID: 3450455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute effects of bromocriptine on gonadotropin secretion in polycystic ovary syndrome.
    Buvat J; Buvat-Herbaut M; Marcolin G; Racadot A; Fourlinnie JC; Fossati P
    Fertil Steril; 1985 Sep; 44(3):356-60. PubMed ID: 3161758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double blind controlled study of the hormonal and clinical effects of bromocriptine in the polycystic ovary syndrome.
    Buvat J; Buvat-Herbaut M; Marcolin G; Racadot A; Fourlinnie JC; Beuscart R; Fossati P
    J Clin Endocrinol Metab; 1986 Jul; 63(1):119-24. PubMed ID: 3519644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bromocriptine treatment of women with clomiphene-resistant polycystic ovary syndrome.
    Polson DW; Mason HD; Franks S
    Clin Endocrinol (Oxf); 1987 Feb; 26(2):197-203. PubMed ID: 3117444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of bromocriptine on endocrine environment in the polycystic ovary syndrome].
    Huang HJ; Ishimaru T; Yamabe T
    Nihon Naibunpi Gakkai Zasshi; 1988 Apr; 64(4):265-78. PubMed ID: 3136040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of bromocriptine on gonadotropin and steroid secretion in polycystic ovarian disease.
    Steingold KA; Lobo RA; Judd HL; Lu JK; Chang RJ
    J Clin Endocrinol Metab; 1986 May; 62(5):1048-51. PubMed ID: 2937800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome.
    Rebar R; Judd HL; Yen SS; Rakoff J; Vandenberg G; Naftolin F
    J Clin Invest; 1976 May; 57(5):1320-9. PubMed ID: 770505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal and clinical effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome.
    Szilágyi A; Homoki J; Bellyei S; Szabó I
    Gynecol Endocrinol; 2000 Oct; 14(5):337-41. PubMed ID: 11109973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bromocriptine in polycystic ovarian disease: a controlled clinical trial.
    el Tabbakh GH; Loutfi IA; Azab I; Rahman HA; Southren AL; Aleem FA
    Obstet Gynecol; 1988 Mar; 71(3 Pt 1):301-6. PubMed ID: 3279350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
    Koo YA; Shin SY; Yoon BK; Choi D
    Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine might not be involved in the pathogenesis of polycystic ovary syndrome.
    Ferriani RA; Silva de Sá MF; Moura MD; Moreira AC; Gomes UA
    Gynecol Endocrinol; 1989 Dec; 3(4):317-27. PubMed ID: 2516707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
    Kazerooni T; Dehghan-Kooshkghazi M
    Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous administration of pulsatile gonadotropin-releasing hormone decreases serum follicle-stimulating hormone and luteinizing hormone levels in women with polycystic ovary syndrome: a preliminary study.
    Graña-Barcia M; Liz-Lestón J; Lado-Abeal J
    Fertil Steril; 2005 May; 83(5):1466-72. PubMed ID: 15866586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
    Eagleson CA; Gingrich MB; Pastor CL; Arora TK; Burt CM; Evans WS; Marshall JC
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effect of bromocriptine treatment on luteinizing hormone secretion in polycystic ovary syndrome.
    Falaschi P; Rocco A; del Pozo E
    J Clin Endocrinol Metab; 1986 Feb; 62(2):348-51. PubMed ID: 3510225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute effects of L-dopa and bromocriptine on serum PRL, LH and FSH levels in patients with hyperprolactinemic and normoprolactinemic polycystic ovary syndrome.
    Prelević GM; Würzburger MI; Perić LA
    J Endocrinol Invest; 1987 Aug; 10(4):389-95. PubMed ID: 3119696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistant cases of polycystic ovarian disease successfully treated with a combination of corticosteroids, clomiphene, and bromocriptine.
    Homburg R; Ashkenazi J; Goldman J
    Int J Fertil; 1988; 33(6):393-7. PubMed ID: 2906913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective, double-blind, randomized, placebo-controlled clinical trial of bromocriptine in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level.
    Parsanezhad ME; Alborzi S; Jahromi BN
    Int J Fertil Womens Med; 2002; 47(6):272-7. PubMed ID: 12570169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.